HERA-LIGHT
/ Apogenix
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 16, 2018
Novel hexavalent HVEM agonist HERA-LIGHT promotes T cell activation and expansion
(AACR 2018)
- "In vivo, treatment with a murine surrogate of HERA-LIGHT resulted in significant tumor growth inhibition in a pilot study using the syngeneic CT-26 colorectal cancer model.In summary, the unique hexavalent design of HERA-LIGHT mediates efficient co-stimulation of Teff even in the presence of Treg cells and independent of secondary crosslinking events. Being true agonists, all HERA molecules are unique from current antibody-based concepts rendering them attractive candidates for cancer immunotherapy."
Colorectal Cancer
1 to 1
Of
1
Go to page
1